文献速递慢性肾脏病肾血管病与高血压

GLP-1受体激动剂与CKD患者主要不良心血管事件风险

Glucagon-like Peptide-1 Receptor Agonists and Risk of Major Adverse Cardiovascular Events in Patients With CKD.
PubMed 文献 · Am J Kidney Dis · 2025-11-12

在加拿大安大略省eGFR<90 mL/min/1.73 m2的成人中,比较GLP1-RA与DPP-4抑制剂新使用者的MACE风险。回顾性队列显示GLP1-RA组MACE发生率较低(SHR 0.88,95%CI 0.80-0.97),主要与心血管死亡减少相关(SHR 0.72,95%CI 0.62-0.85),不同CKD分期无效应修饰。

要点

  • GLP1-RA较DPP-4抑制剂降低CKD患者MACE风险(SHR 0.88)
  • 获益主要来自心血管死亡减少(SHR 0.72)
  • 不同CKD分期及是否联用SGLT2抑制剂间效应一致

核心结论

  • 在CKD人群中,起始GLP1-RA与较DPP-4抑制剂起始更低的主要不良心血管事件发生率相关。

研究设计与样本

  • 回顾性观察性队列研究,纳入加拿大安大略省GLP1-RA新使用者24,576例和DPP-4抑制剂新使用者44,367例,eGFR<90 mL/min/1.73 m2。

主要发现

  • GLP1-RA组MACE发生1,296例(31.6/1000人年),DPP-4抑制剂组1,374例(36.5/1000人年),SHR 0.88(95%CI 0.80-0.97)。
  • 心血管死亡SHR 0.72(95%CI 0.62-0.85)。
  • 亚组分析显示CKD分期、白蛋白尿程度及联用SGLT2抑制剂均无效应修饰。

临床怎么用

  • 对合并CKD的2型糖尿病患者,可考虑优先选用GLP1-RA以降低MACE风险。

局限性

  • 回顾性设计。
  • 白蛋白尿信息缺失较多。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: There are limited real-world data describing the cardiovascular benefits of glucagon-like peptide-1 receptor agonists (GLP1-RAs) across the spectrum of chronic kidney disease (CKD) severity. This study evaluated the association of GLP1-RAs with major adverse cardiovascular events (MACE) in comparison with dipeptidyl peptidase-4 (DPP-4) inhibitors in the setting of CKD. STUDY DESIGN: Retrospective observational cohort study. SETTING & PARTICIPANTS: 24,576 new users of GLP1-RA and 44,367 new users of DPP-4 inhibitors with estimated glomerular filtration rate (eGFR) < 90 mL/min/1.73 m2 in Ontario, Canada. EXPOSURE: New use of GLP1-RAs versus DPP-4 inhibitors. OUTCOME: The primary outcome was MACE, comprising nonfatal myocardial infarction, unstable angina, nonfatal ischemic stroke or transient ischemic attack, coronary revascularization, and cardiovascular death. Secondary outcomes included individual components of the composite outcome, hospitalization or emergency department visits for congestive heart failure, peripheral vascular disease revascularization, lower limb amputation, and all-cause mortality. ANALYTICAL APPROACH: Inverse probability of treatment weighting using propensity scores was used to minimize confounding. Multivariable Fine-Gray subdistribution hazard models stratified by eGFR subgroup were fit to evaluate the primary outcome. FINDINGS: Mean age of study participants was 69 years, 50% were female, 92% had type 2 diabetes mellitus, 40% were taking a sodium/glucose cotransporter 2 (SGLT2) inhibitor, and 41% had CKD stages 3-5. MACE occurred among 1,296 (31.6 per 1,000 person-years) GLP1-RA users versus 1,374 (36.5 per 1,000 person-years) DPP-4 inhibitor users (subdistribution hazard ratio [SHR], 0.88 [95% CI, 0.80-0.97]). The lower rate of MACE among GLP1-RA users was largely related to a lower rate of cardiovascular death (SHR, 0.72 [95% CI, 0.62-0.85]). In subgroup analyses, there was no effect modification between the association of GLP1-RA initiation and lower rates of MACE by CKD stages, degree of albuminuria, or concomitant use of SGLT2 inhibitors. LIMITATIONS: Retrospective design. A substantial amount of missing information on albuminuria. CONCLUSIONS: In a population-based study of individuals across the spectrum of kidney disease, GLP1-RA initiation was associated with a lower rate of MACE than initiation of DPP-4 inhibitors. PLAIN-LANGUAGE SUMMARY: A class of medications called glucagon-like peptide-1 receptor agonists (GLP1-RA) is now used for the treatment of diabetes. This study explored the association of GLP1-RA administration with cardiac health in people with kidney disease compared with another common class of diabetes medication, dipeptidyl peptidase-4 (DPP-4) inhibitors. In this study of nearly 69,000 individuals in Ontario, Canada, with a wide range of kidney function, people taking GLP1-RA experienced a lower rate of heart disease than those taking DPP-4 inhibitors. The lower rate was mainly related to fewer deaths from heart disease. Differences were consistent across different levels of kidney disease and regardless of whether people were also taking other medications that protect the heart.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Yau K, Ray JG, Jeyakumar N, et al. Glucagon-like Peptide-1 Receptor Agonists and Risk of Major Adverse Cardiovascular Events in Patients With CKD. Am J Kidney Dis. 2025. PMID: 41238166. doi:10.1053/j.ajkd.2025.09.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。